Drugs / BA1301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06927349 | Jan 2023 → Jun 2026 overdue | neoplasm | Shandong Boan Biotechnology Co., Ltd | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-10-21 | Luye Pharma Group Ltd. | 博安生物靶向CLDN18.2 ADC(BA1301)研究进展亮相ESMO 2025 luye.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BA1301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06927349 ↗ |
| Route | Intravenous | “BA1301 is administered intravenously once every three weeks.” NCT06927349 ↗ |